NCT06664151 A Phase 0 Window of Opportunity Trial of Intratumoral Seasonal Influenza Immunization in Cutaneous Squamous Cell Carcinoma (CSCC) Patients Awaiting Curative Excision

Trial Parameters

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

This study is investigating the effects on immune cells of injecting the influenza vaccine (also known as "flu shot") into cutaneous squamous cell carcinoma (CSCC) tumors prior to having standard-of-care Mohs excision surgery. The study will help understand if the addition of the influenza vaccine could improve the immune system response against the cancer. The names of the study drug involved in this study is: -Fluzone Influenza vaccine (flu shot)

Eligibility Criteria

Inclusion Criteria: * Participants must have a diagnosis of cutaneous squamous cell carcinoma that has been biopsied and confirmed histologically. Mixed histology (such as basosquamous carcinoma, sarcomatous carcinoma) is allowed. * Participants must have a skin tumor that measures 10 - 39 mm (not less than 10 mm and not more than 39 mm) in longest dimension by clinical exam. (Participants may have more than one untreated CSCC at the time of enrollment, but only one CSCC may be treated with the study agent.) * Participants must be candidates for treatment (excision) by Mohs micrographic surgery. * Age ≥18 years. Because CSCC is exceptionally rare in patients \<18 years of age, children are excluded from this study. * ECOG performance status ≤3 (Karnofsky ≥40%, see Appendix A). * Ability to understand and the willingness to sign a written informed consent document. * For participants with a past medical history of Human immunodeficiency virus (HIV), they must be on effective anti-retrov

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.